Thalassemia Treatment Market Players, Trends, Segmentation Analysis and Forecast to 2027
Thalassemia is an inherited blood disorder that is characterized by
inadequate hemoglobin and fewer red blood cells in the body than normal.
Hemoglobin is the substance in red blood cells that allows them to carry
oxygen. The inadequate hemoglobin and fewer red blood cells of thalassemia may
cause anemia.
According to MRFR analysis, Thalassemia
Treatment Market is expected to
register a Moderate CAGR during the forecast period.
The growth of the Global Thalassemia Treatment Market is driven by
various factors such as rising incidence of thalassemia, increasing pipeline
drugs in thalassemia, rise in awareness regarding available treatment options
for the treatment of thalassemia, growing public awareness related to
preventive care and rise in demand for improved curative gene therapy. However,
stringent regulatory policies and high treatment costs are expected to curb the
growth of the global thalassemia treatment market.
The global thalassemia treatment market is currently dominated by
several market players. The key players are involved in product launches and
strategic collaborations to strengthen their market positions.
Major Key
Players:
Some of the Key Players in the Global Thalassemia
Treatment Market Players are Novartis AG
(Switzerland), Kiadis Pharma (Netherlands), Sangamo Therapeutics (US), Gamida
Cell (Israel), Acceleron Pharma, Inc. (US), CELGENE CORPORATION (US), and
Bluebird Bio, Inc. (US).
Segment Analysis
The Global Thalassemia Treatment Market has been
segmented based on type, treatment, and end-user.
The market, based on type, has been divided into
alpha-thalassemia and beta-thalassemia. The alpha-thalassemia segment is likely
to be the fastest during the forecast period as there is an increased incidence
of alpha-globin disorders in the US and other Western nations.
The global thalassemia treatment market has been
segmented based on treatment, into blood transfusions, iron chelation therapy, folic acid supplements, thalassemia
gene therapy, and bone marrow transplants. The blood transfusions segment
is expected to be the fastest market as low risks are involved due to careful
blood screening. For instance, about 56,000 population have major thalassemia,
and there are at least 30,000 people that need regular blood transfusions to
survive and 5,500 die perinatally due to alpha-thalassemia major. As a result,
increasing the need for blood transfusions would boost the growth of the
thalassemia treatment market.
The end-user segment of the market includes
hospitals and clinics, diagnostic laboratories, and others. The hospitals and
clinics segment is expected to hold the largest share of the market due to the
increase in the number of hospital admissions for the treatment of thalassemia
across the globe.
Regional Analysis
The market has been divided, by
region, into the Americas, Europe, Asia-Pacific, and the Middle East &
Africa. The Americas is expected to be the largest market owing to the
increasing prevalence of thalassemia and rising per capita healthcare
expenditure. The thalassemia treatment market in the Americas has further been
branched into North America and Latin America, with the North American market divided
into the US and Canada. The European thalassemia treatment market has been
categorized as Western Europe and Eastern Europe. The Western European market
has further been classified as Germany, France, the UK, Italy, Spain, and the
rest of Western Europe. The thalassemia treatment market in Asia-Pacific has
been segmented into Japan, China, India, South Korea, Australia, and the rest
of Asia-Pacific. Increasing government initiatives to promote the thalassemia
treatment technique is expected to boost the growth of the thalassemia
treatment market in Asia-Pacific and is expected to be the fastest-growing. The
thalassemia treatment market in the Middle East & Africa has been divided
into the Middle East and Africa.
About Market Research
Future
At Market Research Future (MRFR), we enable our
customers to unravel the complexity of various industries through our Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients. Our
market research studies by products, services, technologies, applications, end
users, and market players for global, regional, and country level market
segments, enable our clients to see more, know more, and do more, which help to
answer all their most important questions.
In order to stay updated with technology and work
process of the industry, MRFR often plans & conducts meet with the industry
experts and industrial visits for its research analyst members.
Contact us:
Market Research Future
(part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312
Also Check: Wantstats charts and Stats
Comments
Post a Comment